08048035968
Premium Exporter of Genuine RASCASE 1.5mg Injection from India to Singapore – Orchard | Phoenix Exim

1. General Information

RASCASE 1.5 mg Injection is an oncology-supportive medicine containing Rasburicase. It is primarily used to manage elevated plasma uric acid in patients with certain cancers who are receiving anticancer therapy that may cause Tumor Lysis Syndrome (TLS).

Tumor Lysis Syndrome can occur when cancer cells break down rapidly and release intracellular substances, including purines that are subsequently converted into uric acid. Excessive uric acid can contribute to kidney complications. Rasburicase helps rapidly reduce uric acid levels.

2. Product Information

ParticularInformation
Brand NameRASCASE
Active IngredientRasburicase
Strength1.5 mg
Dosage FormInjection / Lyophilized powder for reconstitution
RouteIntravenous (IV)
Therapeutic ClassRecombinant urate-oxidase / Uricolytic agent
Primary UseManagement of elevated uric acid associated with anticancer therapy
Prescription StatusPrescription medicine
StorageRefrigerate at 2°C–8°C; do not freeze

The RASCASE product is described by the manufacturer as a 1.5 mg rasburicase injection for intravenous administration.

3. Uses of RASCASE 1.5 mg Injection

RASCASE may be used for:

  • Management of elevated uric acid associated with anticancer treatment.
  • Initial management of uric acid in patients at risk of or experiencing Tumor Lysis Syndrome.
  • Patients with leukemia, lymphoma, and certain solid tumors receiving anticancer therapy expected to cause rapid tumor breakdown.
  • Reducing the risk of complications associated with excessive uric acid levels.

4. Benefits of RASCASE 1.5 mg Injection

The major therapeutic benefit of rasburicase is its rapid enzymatic reduction of uric acid.

  • Converts poorly soluble uric acid into allantoin, which is substantially more soluble and easier for the body to eliminate.
  • Helps rapidly lower plasma uric acid.
  • Helps reduce the risk of uric-acid-related kidney complications during high-risk anticancer treatment.
  • Provides supportive management of Tumor Lysis Syndrome in appropriate patients.

5. Side Effects of RASCASE 1.5 mg Injection

Like other medicines, RASCASE can cause side effects. Some are mild, while others can require urgent medical attention.

Reported adverse effects include:

  • Nausea
  • Vomiting
  • Fever
  • Headache
  • Abdominal pain
  • Diarrhea
  • Constipation
  • Peripheral swelling/edema
  • Anxiety
  • Rash
  • Changes in liver enzymes
  • Low phosphate levels

Serious reactions can include severe hypersensitivity/anaphylaxis, hemolysis, and methemoglobinemia.

6. Common Side Effects

Some commonly reported adverse reactions include:

  • Nausea
  • Vomiting
  • Fever
  • Headache
  • Abdominal discomfort
  • Diarrhea
  • Constipation
  • Edema
  • Anxiety
  • Rash

The prescribing information reports several of these reactions among the more frequent adverse reactions observed with rasburicase.

If a patient develops difficulty breathing, chest tightness, facial or throat swelling, severe dizziness, bluish discoloration, or symptoms suggestive of an allergic or blood-related reaction, immediate medical attention is required.

7. How to Use RASCASE 1.5 mg Injection

RASCASE should not be self-administered. It is given by a doctor, nurse, or other qualified healthcare professional through intravenous infusion.

The dosage and duration depend on the patient's clinical condition and the treating oncologist's protocol. The current U.S. prescribing information for rasburicase specifies 0.2 mg/kg by IV infusion over 30 minutes once daily for up to 5 days for the U.S. reference product; the exact regimen for a particular RASCASE product and patient must be determined by the treating physician.

8. How RASCASE Works

RASCASE contains rasburicase, a recombinant urate-oxidase enzyme.

Normally, humans convert purines into uric acid, which is relatively poorly soluble. Rasburicase enzymatically converts uric acid into allantoin, a more soluble and readily excreted metabolite. This produces a rapid reduction in circulating uric acid.

This mechanism makes rasburicase particularly useful when rapid control of uric acid is needed during anticancer treatment.

9. Safety Advice for RASCASE 1.5 mg Injection

  • G6PD deficiency: Rasburicase is contraindicated in patients with G6PD deficiency because it can cause potentially severe hemolysis. Patients at increased risk should be screened before treatment where clinically appropriate.
  • Allergy: Do not use in patients with a previous severe hypersensitivity or anaphylactic reaction to rasburicase.
  • Methemoglobinemia: Rasburicase can cause methemoglobinemia and should be discontinued if this develops.
  • Pregnancy: Rasburicase may cause fetal harm; pregnancy status and potential risks should be discussed with the treating physician.
  • Breastfeeding: Breastfeeding is not recommended according to the U.S. prescribing information.
  • Blood testing: Rasburicase can continue breaking down uric acid in blood samples after collection. Proper sample handling is therefore important to avoid falsely low uric-acid results.
  • Storage: Keep refrigerated at 2°C–8°C and do not freeze.
  • Use only under medical supervision and according to the prescribing physician's instructions.

10. FAQs

Q1. What is RASCASE 1.5 mg Injection?
RASCASE is an injectable formulation containing Rasburicase 1.5 mg, a recombinant urate-oxidase used to rapidly reduce uric acid associated with anticancer treatment.

Q2. What is RASCASE used for?
It is used for the management of elevated uric acid associated with anticancer therapy and Tumor Lysis Syndrome risk in appropriate oncology patients.

Q3. How is RASCASE administered?
It is administered by intravenous infusion by a qualified healthcare professional. It should not be self-injected.

Q4. Can patients with G6PD deficiency use RASCASE?
No. Rasburicase is contraindicated in patients with G6PD deficiency because of the risk of hemolysis.

Q5. How should RASCASE be stored?
The product should generally be refrigerated at 2°C–8°C and protected from freezing. Product-specific storage instructions should be followed.

Q6. Does RASCASE lower uric acid quickly?
Yes. Rasburicase is designed to produce a rapid enzymatic reduction in plasma uric acid.

Q7. Can RASCASE cause an allergic reaction?
Yes. Serious hypersensitivity, including anaphylaxis, can occur and requires immediate medical management.

Q8. Can RASCASE be used during pregnancy?
Pregnancy requires careful medical assessment because rasburicase may cause fetal harm. Patients should inform their healthcare provider if they are pregnant or planning pregnancy.

11. Substitutes for RASCASE 1.5 mg Injection

Possible alternatives containing rasburicase 1.5 mg include products such as:

  • Rasburnat 1.5 mg Injection
  • Rasuric 1.5 mg Injection
  • Rasbelon Injection
  • Other locally approved rasburicase 1.5 mg products

Availability and regulatory status vary by country. A substitute should only be selected by a healthcare professional after confirming the active ingredient, strength, formulation, manufacturer, and patient's clinical requirements.

12. SEO Keywords

Primary Keywords:

  • RASCASE 1.5 mg Injection
  • Rascase Injection
  • Rascase 1.5 mg
  • Rasburicase 1.5 mg Injection
  • Rasburicase Injection
  • Rasburicase 1.5 mg Vial
  • Tumor Lysis Syndrome Injection
  • Rasburicase for Tumor Lysis Syndrome
  • High Uric Acid Chemotherapy Medicine

Long-Tail B2B / Export Keywords:

  • RASCASE 1.5 mg Injection exporter from India
  • RASCASE 1.5 mg Injection supplier from Nagpur India
  • Rasburicase 1.5 mg Injection pharmaceutical exporter India
  • RASCASE Injection supplier for international markets
  • Rasburicase 1.5 mg Injection wholesale supplier India
  • RASCASE 1.5 mg oncology injection exporter
  • Rasburicase Injection exporter to USA
  • Rasburicase Injection exporter to UK
  • Rasburicase Injection exporter to Australia
  • Rasburicase Injection exporter to Singapore
  • Rasburicase Injection exporter to Canada
  • Rasburicase Injection exporter to South Korea
  • Rasburicase Injection exporter to UAE
  • RASCASE 1.5 mg Injection supplier from Nagpur
  • Tumor Lysis Syndrome medicine exporter from India
  • Oncology injection supplier from India
  • Rasburicase 1.5 mg pharmaceutical supplier
  • RASCASE 1.5 mg medicine export supplier
  • Genuine Rasburicase 1.5 mg Injection supplier India
  • Prescription oncology medicine exporter India
Aug 20th, 2026 3:03 PM

Keywords